FSSAI Orders Removal of ‘ORS’ from Food and Beverage Labels

New Delhi– The Food Safety and Standards Authority of India (FSSAI) has directed all food and beverage manufacturers to immediately remove the term “ORS” (Oral Rehydration Solution) from product labels, citing misleading claims about health benefits.

The order aims to prevent consumer confusion, as only medically certified ORS products can use the term. Non-compliance will attract fines up to ₹10 lakh. Manufacturers have 30 days to update packaging. FSSAI emphasized stricter enforcement to protect public health.

Background: Public Interest Litigation

The regulatory intervention follows a nearly decade-long campaign by Hyderabad-based paediatrician Dr. Sivaranjani Santosh against sugar-rich beverages falsely marketed as ORS. In 2022, she filed a Public Interest Litigation (PIL) in the Telangana High Court challenging beverages that claimed to be ORS but failed to meet WHO-recommended electrolyte and glucose standards.

Her petition highlighted the potential health risks, especially to children and diabetic patients, and her complaints reached the Ministry of Health and Family Welfare, prompting regulatory scrutiny.

Court and Regulatory Actions

The Telangana High Court directed FSSAI and the Drug Controller General of India to respond, recognising the public health implications of misleading ORS claims.

In April 2022, FSSAI issued its first restriction, but in July the regulator temporarily allowed companies holding valid trademarks to continue production until the Controller General of Patents, Designs and Trademarks issued a final decision.

Health Risks from Mislabelled Beverages

WHO-approved ORS has a total osmolarity of 245 mOsm/L, with precise quantities of sodium, potassium, chloride, and dextrose. In contrast, many marketed products contained up to 120 grams of sugar per litre, with minimal electrolytes, posing serious health risks.

Related Posts

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care